ArticleJournal of natural medicines2025
Multi-omics analysis reveals the mechanism of action of Atractylodin against depression.
Article in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities.Biochemistry and biophysics reports · 2026Review
- A systematic review on the application, phytochemistry and pharmacological activities of the genus Atractylodes.Chinese medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Atractylodin (ATR) is a natural sesquiterpene compound primarily isolated from the rhizomes of Atractylodes, a plant of the Asteraceae family. It is the core bioactive component of the traditional Chinese medicine Atractylodes and has been confirmed to possess anti-inflammatory, antioxidant, and neuroregulatory functions in various disease models. Recent studies have highlighted ATR's significant roles in anti-tumor, anti-inflammatory, and immune-regulatory activities. However, it remains unclear whether ATR can alleviate depression and its potential pharmacological mechanisms. Our study demonstrates that ATR treatment alleviated depression-like behaviors and improved neuronal changes in the hippocampus of rats. Transcriptomic and proteomic analyses revealed that ATR exerted its antidepressant effects primarily through the regulation of ferroptosis and synaptic plasticity. ATR increased the expression of IL-10, SOD, and GSH, while reducing IL-1β, TNF-α, MDA, and ROS levels, thereby improving inflammation and oxidative stress. Immunohistochemical results indicated that ATR treatment significantly increased the expression of GPX4, SLC7A11, BDNF and NRF2 proteins. This study demonstrates that ATR significantly alleviates depressive symptoms in CUMS rats, with its mechanism primarily involving the regulation of ferroptosis and improvement of synaptic plasticity. ATR may be a potential candidate as an antidepressant.
Indexed as
Identifiers
40613961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.